Atossa Therapeutics (ATOS) Non Operating Interest Expenses (2011 - 2015)

Atossa Therapeutics (ATOS) has reported Non Operating Interest Expenses for 5 consecutive years, with $1784.0 the latest figure, recorded in Q1 2015.

• On a quarterly basis, Non Operating Interest Expenses rose 138.18% year-over-year to $1784.0 in Q1 2015; TTM through Mar 2015 was $16804.0, a 1424.86% increase from a year earlier, with the FY2014 full-year figure at $15769.0, up 4280.28% from the prior year.
• Non Operating Interest Expenses was $1784.0 for Q1 2015 at Atossa Therapeutics, down from $13426.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $13426.0 in Q4 2014 and troughed at $1.0 in Q3 2013.
• A 5-year average of $2879.6 and a median of $1100.5 in 2011 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses slumped 99.99% in 2013 and surged 15000.0% in 2014, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $9604.0 in 2011, then sank by 97.67% to $224.0 in 2012, then slumped by 99.55% to $1.0 in 2013, then surged by 1342500.0% to $13426.0 in 2014, then slumped by 86.71% to $1784.0 in 2015.
• The last three Non Operating Interest Expenses figures came in at $1784.0 (Q1 2015), $13426.0 (Q4 2014), and $151.0 (Q3 2014), per Business Quant data.